Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences (KOD)
:KOD
KOD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.92 - $11.60
Previous CloseN/A
Volume87.32K
Average Volume (3M)439.08K
Market Cap
$217.12M
Enterprise Value$526.14M
Total Cash (Recent Filing)-$9.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.30
Next Earnings
May 19, 2025EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding52,763,542
10 Day Avg. Volume489,974
30 Day Avg. Volume439,082
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$9.00Price Target Upside118.45% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Kodiak Sciences News
---
Bulls Say, Bears Say
Bulls Say
Market InterestKodiak Sciences is witnessing excellent receptivity from healthcare funds, indicating strong interest at current valuation.
Stock ValuationKOD's stock is considered very cheap just above cash and is expected to climb as big Phase III data approaches.
Strategic PositioningThe company has taken appropriate strategic steps to position the ABCD platform for its best shots on goal, focusing on enhanced formulation tarcocimab and other trials.
Bears Say
Historical ChallengesInvestors are reminded of the prior late-stage failures for tarcocimab in the Phase 3 GLEAM and GLIMMER trials in DME, unexpected increase in cataract AEs over time for tarcocimab, and the Phase 2b/3 DAZZLE trial failure in wet AMD.
Past Trial FailuresKodiak continues to turn the page from its previous late-stage tarcocimab setbacks, including the Phase 3 GLEAM and GLIMMER trial failures in DME and the Phase 2b/3 DAZZLE trial failure in wet AMD.
---
Ownership Overview
34.73% Insiders
8.19% Mutual Funds
48.88% Other Institutional Investors
0.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KOD FAQ
What was Kodiak Sciences’s price range in the past 12 months?
Kodiak Sciences lowest stock price was $1.92 and its highest was $11.60 in the past 12 months.
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $217.12M.
When is Kodiak Sciences’s upcoming earnings report date?
Kodiak Sciences’s upcoming earnings report date is May 19, 2025 which is in 21 days.
How were Kodiak Sciences’s earnings last quarter?
Kodiak Sciences released its earnings results on Mar 27, 2025. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.883 by $0.043.
Is Kodiak Sciences overvalued?
According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued.
Does Kodiak Sciences pay dividends?
Kodiak Sciences does not currently pay dividends.
What is Kodiak Sciences’s EPS estimate?
Kodiak Sciences’s EPS estimate is -0.89.
How many shares outstanding does Kodiak Sciences have?
Kodiak Sciences has 52,763,542 shares outstanding.
What happened to Kodiak Sciences’s price movement after its last earnings report?
Kodiak Sciences reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.883. Following the earnings report the stock price went down -4.902%.
Which hedge fund is a major shareholder of Kodiak Sciences?
Currently, no hedge funds are holding shares in KOD
---
Kodiak Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.00 (118.45% Upside)
$9.00 (118.45% Upside)
Blogger Sentiment
Neutral
KOD Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 112.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.19%
12-Months-Change
Fundamentals
Return on Equity
-84.70%
Trailing 12-Months
Asset Growth
-30.00%
Trailing 12-Months
Company Description
Kodiak Sciences
Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California, and operates within the biotechnology and pharmaceutical sectors. Its core product candidate is KSI-301, an investigational therapy designed to improve outcomes for patients with retinal vascular diseases such as wet age-related macular degeneration and diabetic eye diseases.
---
KOD Stock 12 Month Forecast
Average Price Target
$9.00
▲(118.45% Upside)
Technical Analysis
Aldeyra Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Neumora Therapeutics, Inc.
―
Best Analysts Covering KOD
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+47.98%
reiterated a sell rating last month
Copying Gena Wang's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +47.98% per trade.
---